Organogenesis Holdings Inc.

NasdaqCM:ORGO 주식 보고서

시가총액: US$326.1m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Organogenesis Holdings 관리

관리 기준 확인 3/4

Organogenesis Holdings' CEO는 Gary Gillheeney, Jan2014 에 임명되었습니다 의 임기는 10.42 년입니다. 총 연간 보상은 $ 6.24M, 14.6% 로 구성됩니다. 14.6% 급여 및 85.4% 보너스(회사 주식 및 옵션 포함). 는 $ 2.08M 가치에 해당하는 회사 주식의 0.63% 직접 소유합니다. 2.08M. 경영진과 이사회의 평균 재임 기간은 각각 6.8 년과 3.6 년입니다.

주요 정보

Gary Gillheeney

최고 경영자

US$6.2m

총 보상

CEO 급여 비율14.6%
CEO 임기10.4yrs
CEO 소유권0.6%
경영진 평균 재임 기간6.8yrs
이사회 평균 재임 기간3.6yrs

최근 관리 업데이트

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Sep 23
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Aug 15

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Jul 28
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Jun 10
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis Holdings: What Now

May 18

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

Mar 31
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Mar 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Nov 30
Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

CEO 보상 분석

Gary Gillheeney 의 보수는 Organogenesis Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

US$6m

Dec 31 2023US$6mUS$909k

US$5m

Sep 30 2023n/an/a

US$13m

Jun 30 2023n/an/a

US$10m

Mar 31 2023n/an/a

US$13m

Dec 31 2022US$6mUS$883k

US$16m

Sep 30 2022n/an/a

US$59m

Jun 30 2022n/an/a

US$71m

Mar 31 2022n/an/a

US$83m

Dec 31 2021US$4mUS$835k

US$94m

Sep 30 2021n/an/a

US$62m

Jun 30 2021n/an/a

US$69m

Mar 31 2021n/an/a

US$43m

Dec 31 2020US$3mUS$823k

US$17m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$819k

-US$39m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$58m

Dec 31 2018US$3mUS$798k

-US$65m

Sep 30 2018n/an/a

-US$60m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$32m

Dec 31 2017US$1mUS$780k

-US$9m

보상 대 시장: Gary 의 총 보상 ($USD 6.24M )은 US 시장( $USD 2.46M ).

보상과 수익: Gary 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Gary Gillheeney (69 yo)

10.4yrs

테뉴어

US$6,244,671

보상

Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...

리더십 팀

이름위치테뉴어보상소유권
Gary Gillheeney
President10.4yrsUS$6.24m0.63%
$ 2.1m
David Francisco
Chief Financial Officer3.3yrsUS$1.63m0.048%
$ 157.1k
Patrick Bilbo
Chief Operating Officer6.8yrsUS$2.16m0.26%
$ 853.8k
Lori Freedman
Chief Administrative & Legal Officer7.4yrsUS$1.99m0.063%
$ 206.4k
Brian Grow
Chief Commercial Officer6.8yrsUS$1.92m0.078%
$ 255.4k
William Kolb
Secretaryno data데이터 없음데이터 없음
Robert Cavorsi
Vice President of Strategy3.4yrs데이터 없음데이터 없음

6.8yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: ORGO 의 관리팀은 노련하고 경험 (평균 재직 기간 6.8 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Gary Gillheeney
President5.5yrsUS$6.24m0.63%
$ 2.1m
Glenn Nussdorf
Director21.4yrs데이터 없음11.29%
$ 36.8m
Alan Ades
Director21.4yrs데이터 없음11.5%
$ 37.5m
Arthur Leibowitz
Lead Independent Director5.5yrsUS$291.46k0.10%
$ 336.0k
Robert Ades
Director3.6yrs데이터 없음데이터 없음
Jon Giacomin
Independent Director3.1yrsUS$265.00k0.068%
$ 221.0k
Michele Korfin
Independent Director2.1yrsUS$226.98k0.068%
$ 220.5k
Prathyusha Duraibabu
Independent Director2.6yrsUS$240.00k0.071%
$ 230.9k
David Erani
Director3.6yrs데이터 없음데이터 없음
Michael Driscoll
Independent Director2.3yrsUS$230.52k데이터 없음
Gilberto Quintero
Independent Director2.1yrsUS$226.98k0.068%
$ 220.5k

3.6yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: ORGO 의 이사회는 경험(평균 재직 기간 3.6 년)으로 간주됩니다.